Blue­bird to miss Q1 dead­line for lo­vo-cel fil­ing, shares sliced

Blue­bird bio had ex­pect­ed to sub­mit a BLA for its sick­le cell dis­ease gene ther­a­py lovotibeglo­gene au­totem­cel, or lo­vo-cel, by Fri­day. Now, that dead­line is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER